Comment on CMS-2026-1255-0001

Summary: The Association for Clinical Oncology (ASCO) supports the proposed rule to improve electronic prior authorization for drugs, including requirements for specific denial reasons and shortened decision timeframes. They advocate for even more aggressive real-time decision-making, more granular reporting of prior authorization metrics, and direct reporting of this data to CMS to ensure accountability.